about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerSingle-Walled Carbon Nanotubes Inhibit the Cytochrome P450 Enzyme, CYP3A4.CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.High lethality and minimal variation after acute self-poisoning with carbamate insecticides in Sri Lanka - implications for global suicide preventionStructural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4.Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.The Pharmacogenetics of Tramadol.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.CYP3A activity: towards dose adaptation to the individual.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism.Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.Inhibition of salivary secretion by tolterodine transdermal patch.Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study.Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
P2860
Q26741187-356F0E6E-DDFA-4C1F-BACB-F7EF65557EE8Q26775949-6C4A69D2-2F49-4FE1-B610-573B2FC8E85DQ27348354-38D70182-2F18-4E59-B33B-52C9BA87D7D9Q36359679-C8DC70A3-628F-4D7E-9D4B-B61A4D815E7BQ37107312-C953F43A-EBE6-4ACB-A1DA-456B7DF2ECA3Q37598971-54B59509-D944-43B7-9F41-63B28EB00E6BQ37662607-1B65007F-D06E-43C4-AF4D-FE5AD5732E87Q38441114-B2FACFFA-9724-4CAF-B933-B4BFCF15EBB5Q38509732-9E523325-2B0E-46FE-8153-F14D78384377Q38604479-176C4014-3545-4997-AD4A-1F20D0D539A1Q38763583-6E443D45-6248-4BDF-8415-C251F557202DQ38787174-4841E6B9-2870-4A00-A9F5-6677A1A4C228Q38798449-5A1A5D40-5614-4A3D-A39C-F9AA58C6BC60Q38821274-83352B4F-C826-4F81-B0F6-F797EC6D50FCQ38851505-8E9D35A8-F6BB-4BC2-87DE-2336D302ACB3Q38937515-75499AD9-080F-4638-8A83-3D1740758B79Q39183375-AF352F28-4953-4B46-9940-902A4D28B61CQ39752018-6ECA9138-4A11-434C-8E6A-D7BA1C886EB1Q42215557-41B5499D-430C-4B0D-9A00-C86406C7558EQ47096668-CAC4761E-AD0A-4D63-A778-F6553F83FD16Q47309313-A7EF315D-88C4-4D6E-8EEB-7F0686BDD446Q47336853-16D30C44-F77E-42E6-871F-E736B58323F4Q47400081-F1199584-44A5-4409-9524-CE4E44ECF35EQ47424342-28EF5215-A50E-47AF-A4A1-B37B3BEE628DQ47593083-72864CAE-EC05-48C9-829B-8EE3C6E67875Q47664190-64FAC9E0-C3B5-4441-8B4C-81724CB0D535Q47672239-7B53DC65-1263-4F7D-BA51-61F8BA82F4AFQ48009302-4233679D-899D-4308-80C3-B8C6370B6A5BQ48266047-A8FE3F31-1916-4D12-B36D-1193EEB38351Q48320660-31A39C50-4A7C-4085-9324-15C7A8B8818EQ50534806-44765BC7-34D3-4F20-8890-197CA80CCC75Q52815923-296F7AB4-F414-4AC0-B7E6-7BEA75C31491Q52929887-00E71AA2-4BAD-4468-B26D-405F267B0FEEQ53236559-99EE8455-66AD-43ED-BDF5-7201821B7866Q53621686-A5B6137A-C1E0-41E7-8274-5D411C8CA588
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Functional gene variants of CYP3A4.
@en
type
label
Functional gene variants of CYP3A4.
@en
prefLabel
Functional gene variants of CYP3A4.
@en
P2860
P356
P1476
Functional gene variants of CYP3A4
@en
P2093
P2860
P304
P356
10.1038/CLPT.2014.129
P407
P577
2014-06-13T00:00:00Z